[go: up one dir, main page]

NO20065227L - Menoklonale antistoff mot hepatocytt vekstfaktor - Google Patents

Menoklonale antistoff mot hepatocytt vekstfaktor

Info

Publication number
NO20065227L
NO20065227L NO20065227A NO20065227A NO20065227L NO 20065227 L NO20065227 L NO 20065227L NO 20065227 A NO20065227 A NO 20065227A NO 20065227 A NO20065227 A NO 20065227A NO 20065227 L NO20065227 L NO 20065227L
Authority
NO
Norway
Prior art keywords
growth factor
hepatocyte growth
antibody
menoclonal
pharmaceutical composition
Prior art date
Application number
NO20065227A
Other languages
English (en)
Inventor
Jin Kyong Kim
Yi-Chi Su
Lihong Wang
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065227(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of NO20065227L publication Critical patent/NO20065227L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sammendrag Oppfinnelsen er rettet på et nøytraliserende monoklonalt antistoff til hepatocyttvekstfaktor, en farmasøytisk blanding omfattende det samme, og fremgangsmåte for behandling omfattende at en pasient tilføres en slik farmasøytisk blanding, som for eksempel for å inhibere glioblasom.
NO20065227A 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor NO20065227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
NO20065227L true NO20065227L (no) 2007-01-10

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065227A NO20065227L (no) 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor

Country Status (25)

Country Link
US (5) US20040208876A1 (no)
EP (2) EP1734995B1 (no)
JP (2) JP4594381B2 (no)
KR (1) KR101072736B1 (no)
CN (1) CN1964738A (no)
AT (1) ATE473760T1 (no)
AU (1) AU2004319276C1 (no)
BR (1) BRPI0418745A (no)
CA (1) CA2563080C (no)
CR (1) CR8698A (no)
CY (1) CY1110783T1 (no)
DE (1) DE602004028168D1 (no)
DK (1) DK1734995T3 (no)
ES (1) ES2346886T3 (no)
HR (1) HRP20100521T1 (no)
IL (1) IL178474A (no)
MX (1) MXPA06011822A (no)
NO (1) NO20065227L (no)
NZ (1) NZ550324A (no)
PL (1) PL1734995T3 (no)
PT (1) PT1734995E (no)
RU (1) RU2361879C2 (no)
SI (1) SI1734995T1 (no)
WO (1) WO2005107800A1 (no)
ZA (1) ZA200609407B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CN103755807A (zh) * 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
BRPI0611009A2 (pt) * 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
CN101370521A (zh) 2006-01-27 2009-02-18 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
JP4686634B2 (ja) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
EP2029627B1 (en) * 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
JP5699075B2 (ja) * 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
CZ2011514A3 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
CN121358764A (zh) * 2023-05-05 2026-01-16 布坦坦研究所 人抗FGF2单克隆抗体(mAb)、包含其的药物组合物、其用途和用于检测包含所述mAb的生物样品中的癌症的试剂盒

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9110202D0 (en) * 1991-05-10 1991-07-03 Erba Carlo Spa Truncated forms of the hepatocyte growth factor(hgf)receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0922102B1 (en) 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
WO2000012560A1 (en) 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
WO2003010282A2 (en) 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1636593B9 (en) 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
WO2005007193A2 (en) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
CN103755807A (zh) * 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
BRPI0611009A2 (pt) 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
PT1734995E (pt) 2010-08-18
IL178474A0 (en) 2007-02-11
ZA200609407B (en) 2008-07-30
DE602004028168D1 (de) 2010-08-26
AU2004319276A1 (en) 2005-11-17
CA2563080A1 (en) 2005-11-17
AU2004319276C1 (en) 2011-03-03
NZ550324A (en) 2009-12-24
RU2361879C2 (ru) 2009-07-20
US7494650B2 (en) 2009-02-24
EP1734995B1 (en) 2010-07-14
CY1110783T1 (el) 2015-06-10
MXPA06011822A (es) 2007-03-23
US20040208876A1 (en) 2004-10-21
HK1094167A1 (en) 2007-03-23
US20120064066A1 (en) 2012-03-15
ES2346886T3 (es) 2010-10-21
CA2563080C (en) 2015-01-27
US20080019966A1 (en) 2008-01-24
CR8698A (es) 2007-12-17
CN1964738A (zh) 2007-05-16
IL178474A (en) 2011-04-28
PL1734995T3 (pl) 2010-12-31
US20070160613A1 (en) 2007-07-12
SI1734995T1 (sl) 2010-09-30
US7687063B2 (en) 2010-03-30
US20090104192A1 (en) 2009-04-23
JP2011012067A (ja) 2011-01-20
JP2007532643A (ja) 2007-11-15
KR101072736B1 (ko) 2011-10-11
EP2204191A1 (en) 2010-07-07
ATE473760T1 (de) 2010-07-15
KR20070012711A (ko) 2007-01-26
WO2005107800A1 (en) 2005-11-17
EP1734995A4 (en) 2007-04-25
DK1734995T3 (da) 2010-10-25
EP1734995A1 (en) 2006-12-27
AU2004319276B2 (en) 2010-08-26
HRP20100521T1 (hr) 2010-10-31
BRPI0418745A (pt) 2007-12-11
RU2006140257A (ru) 2008-05-20
JP4594381B2 (ja) 2010-12-08

Similar Documents

Publication Publication Date Title
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
ATE437186T1 (de) Anti-epcam-immunoglobuline
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE602004020337D1 (de) Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
DK1838392T3 (da) Selenholdige medikamenter mod endotheliale vaskulære sygdomme
UA2986U (uk) Спосіб лікування розсіяного склерозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application